Menu Close

Trending

Merck makes circular RNA play with $3.5bn Orna alliance
On heels of new data, Gilead pays $455m for Asian Trodelvy rights
Roche eyes April FDA verdict on Polivy as first-line lymphoma therapy
Digital health’s rapid growth spurt comes home to roost
FDA grants swift review to Lynparza in first-line prostate cancer

kantar health

clinical trials

R&D/ Views & Analysis/ Views and analysis

Connecting EHR to clinical trials: How to embrace the promise of real-world data

, , , , , 0 Comment

We all know that real-world data (RWD) from electronic health records (EHR) could boost clinical trial efficiency and

X
Connecting EHR to clinical trials: How to embrace the promise of real-world data
https://pharmaphorum.com/r-d/connecting-ehr-to-clinical-trials-how-to-embrace-the-promise-of-real-world-data/
CernerEnviza---logo-1200x675

Partner content/ Press releases

Cerner Enviza aims to accelerate therapies and improve patient outcomes

, , , 0 Comment

Combining decades of healthcare, life sciences and collaborative research to transform the way care is delivered Kansas City,

X
Cerner Enviza aims to accelerate therapies and improve patient outcomes
https://pharmaphorum.com/partner-content/cerner-enviza-aims-to-accelerate-therapies-and-improve-patient-outcomes/
Touchpoint optimisation

Debates & Insight/ Sales and Marketing/ Sales and Marketing/ Slider in whitepapers/ White Papers

Touchpoint optimisation: time for multichannel marketing to reconnect the brand story and the customer

, , 0 Comment

  As the digital era of communication continues to expand and flourish, the way life sciences companies interact

X
Touchpoint optimisation: time for multichannel marketing to reconnect the brand story and the customer
https://pharmaphorum.com/debates-insight-sales-marketing/touchpoint-optimisation-time-multichannel-marketing-reconnect-brand-story-customer/
Kantar_ASCO Day 5 coverage pic

ASCO-contributor/ Oncology/ Partner content/ Partner Content/ Pharma Market Access/ Press releases

Ibrance approval cemented as competition comes into view

, , , , , 0 Comment

In February 2015,  Pfizer’s Ibrance (palbociclib) was granted accelerated approval by the FDA for treatment of newly diagnosed

X
Ibrance approval cemented as competition comes into view
https://pharmaphorum.com/partner-content-oncology/ibrance-approval-cemented-competition-comes-view/
Kantar_ASCO Day 4 coverage pic

ASCO-contributor/ Market Access/ Oncology/ Partner content/ Partner Content/ Partner Content/ Pharma Market Access/ Press releases

Does NEMO bring us a step closer in the fight against melanoma?

, , , , , , , 0 Comment

Options for treatment in metastatic melanoma have increased significantly in terms of efficacy and reduction of mortality in

X
Does NEMO bring us a step closer in the fight against melanoma?
https://pharmaphorum.com/partner-content-oncology/nemo-bring-us-step-closer-fight-melanoma/
Kantar_ASCO Day 3 coverage pic

ASCO-contributor/ Market Access/ Oncology/ Partner content/ Partner Content/ Partner Content/ Pharma Market Access/ Press releases

Further Darzalex results extend hope for PFS in Myeloma

, , , , , 0 Comment

Earlier this year (March), Johnson & Johnson announced that the randomized Phase III CASTOR trial (NCT02136134) achieved its

X
Further Darzalex results extend hope for PFS in Myeloma
https://pharmaphorum.com/partner-content-oncology/further-darzalex-results-extend-hope-for-pfs-in-myeloma/
1 2

Login

CONTINUE TO SITE >
X
Close in 10 seconds